Poolbeg Pharma US infectious diseases expert, Professor Daniel Hoft, joins Scientific Advisory Board

Poolbeg Pharma plc (LON:POLB) a clinical stage infectious disease pharmaceutical company with a capital light clinical model, has appointed Professor Daniel Hoft to its Scientific Advisory Board.

Prof Hoft, M.D., Ph.D. is the Dianna and J. Joseph Adorjan Endowed Chair of Infectious Diseases and Immunology, and Director of the Division of Infectious Diseases, Allergy & Immunology at Saint Louis University (SLU) School of Medicine. He has been working in immunology and infectious diseases for 32 years. Prof Hoft has published over 140 peer reviewed scientific publications.

Prof Hoft will join the Scientific Advisory Board alongside Dr Elaine Sullivan and Prof Luke O’Neill and with his extensive background in infectious disease, immunology, and vaccinology, will guide the Company on its asset development programmes. Prof Hoft will also work with the Company to scout for prospective in-licencing opportunities.

Prof Hoft is heavily involved in vaccine development research, especially for pandemic influenza and tuberculosis which has seen him undertake pioneering work in T-cell targeting vaccines which is particularly relevant to the Company’s Vaccine Discovery Platform. He is Principal Investigator of the SLU’s Vaccine & Treatment Evaluation Unit (VTEU), one of ten US National Institutes of Health (NIH) centers, placing it among an elite group of top academic centers conducting clinical trials of novel vaccines for global protection against future pandemic challenges. Since the SARS-CoV-2 pandemic the SLU VTEU led by Prof Hoft has featured prominently in the urgent COVID-19 vaccine development and Prof Hoft is the VTEU protocol chair for a first-in-human phase I trial of a novel COVID-19 vaccine. He has received numerous awards from NIH, US Department of Defense, and the Bill & Melinda Gates Foundation and is a regular advisor to the World Health Organisation.You might also enjoy reading  Poolbeg Pharma Rapidly progressing towards LPS challenge study

Read Prof Hoft’s full bio on Poolbeg’s website.

Jeremy Skillington, PhD, CEO of Poolbeg Pharma, said: “Prof Hoft is a great addition to the Poolbeg Scientific Advisory Board, joining Dr Elaine Sullivan and Prof Luke O’Neill. His expertise in infectious disease, particularly with severe influenza and vaccine development will be invaluable as we develop Poolbeg’s pipeline of assets. He will also work with the Company to scout for prospective assets to in-licence and develop. Prof Hoft is a widely respected specialist within our industry and we look forward to working with him as we continue our growth journey.” 

Prof Daniel Hoft, M.D., Ph.D., commented:

“Poolbeg has an interesting portfolio of assets within infectious disease with an exciting lead asset, POLB 001. Coupled with its unique access to 20 years’ of human viral challenge study data, means its approach has real potential in this space. I look forward to helping support the business as it develops.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
Twitter
LinkedIn
Poolbeg Pharma

More articles like this

Reducing cancer immunotherapy-induced CRS

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Key AI trends in Drug Discovery

2023 was the year of AI. It would be difficult to finish your day without seeing or hearing at least 5 updates about developments related to AI, ChatGPT or language models. The year was marked by

DirectorsTalk

Companies to follow in 2024

Here we look at 10 companies from a variety of sectors that have performed in 2023, or which may be positioned for a better year ahead. Also look out for our roundups of oil and gas

5 ways pharma can safely leverage AI for drug discovery

In recent years, those applying computer science to biology have had no trouble raising the money to take their innovations straight into the commercial world. The promise was simple: get your hands on large datasets and

Poolbeg Pharma: Year in Review 2023

Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model. 

Poolbeg identifies strategic drug targets for treatment of RSV

Biopharmaceutical company Poolbeg has selected as strategic priority a number of potential treatments for Respiratory Syncytial Virus. The drug targets were selected from a list identified as part of Poolbeg’s artificial intelligence-led programme, which identified the

Poolbeg Pharma says used AI to identify RSV drug targets

Poolbeg Pharma says it has successfully used artificial intelligence to identify drug targets for the treatment of Respiratory Syncytial Virus (RSV). The programme identified the RSV drug treatment candidates in just 10 months, the company said

Poolbeg Pharma

How Generative AI is shaping the future of pharma

In the past year, generative artificial intelligence (GAI) has emerged as a potentially groundbreaking force in the pharmaceutical industry. This technology, which involves AI systems that can generate novel data and insights, could very well become

Poolbeg Pharma

M&A trends in AI for drug discovery

Advances in AI promise to transform drug discovery and development. AI not only brings more efficiency to today’s costly and slow processes but also holds the potential to identify entirely new drugs beyond the capabilities of

Poolbeg Pharma

Poolbeg Pharma presented POLB 001 data at American Society of Hematology

Poolbeg Pharma (LON:POLB, OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need and with a lack of treatment alternatives, has announced key insights from its poster presentation

Poolbeg Pharma

Poolbeg Pharma could reach €1bn valuation

Poolbeg Pharma, the Dublin-headquartered biopharmaceutical company, could reach a €1 billion valuation, according to Jeremy Skillington, its chief executive. Skillington compared the potential of Poolbeg to that of Amryt Pharma, which was sold to Chiesi Farmaceutici